Very frustrating, to say the least, given that had ARRY acted timely, they could have easily raised funds with the share price above $5, if not $6 I'm sure many R and D bio CEO's are thinking the very same thing right now. Oh how the tides have turned in biotech land in a few short weeks. There are quite a few Biotech Values out there right now.